Durham, NC-based Chimerix ($CMRX) tried to put the best spin possible on the failure of a mid-stage study of brincidofovir (CMX001), its lead antiviral. Investigators tested the antiviral among hematopoietic cell transplant recipients with early adenovirus infection, but said--well into its release--that the therapy fell short on achieving statistical significance on efficacy in the "progression to possible or probable AdV disease or significant changes in AdV viremia. Chimerix launched a hot IPO earlier this year and its stock was barely dented today. "The acceptable safety and tolerability of CMX001, and successful incorporation of the Safety Monitoring and Management Plan in this study, were important milestones for the brincidofovir program as we initiate dosing in the Phase 3 SUPPRESS trial for CMV prevention in HCT recipients," said